Determination of minimal clinically important change in early and advanced Parkinson's disease

Movement Disorders

Volumn 26, Issue 5, 2011, Pages 813-818

  Hauser, Robert A ^a   Auinger, Peggy ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Clinical global impression; Clinical trial; Minimal clinically important change; Parkinson's disease; Treatment

Indexed keywords

LEVODOPA; PLACEBO; RASAGILINE;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG EFFICACY; FALSE POSITIVE RESULT; HUMAN; MAJOR CLINICAL STUDY; MINIMAL CLINICALLY IMPORTANT CHANGE; MOTOR DYSFUNCTION; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SELF CONCEPT; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE;

ANTIPARKINSON AGENTS; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDANS; LEVODOPA; MALE; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PLACEBO EFFECT; ROC CURVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 79955101051     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23638     Document Type: Article

References (15)

1. Fahn S, Elton RL, UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan; 1987: 153-163.
2. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002; 59: 1937-1943.
3. Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F, on behalf of the 056 Study Group. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. Mov Disord. 1998; 13: 39-45.
4. Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S, for the 053 Study Group. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. Neurology. 1999; 53: 364-370.
5. Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F, on behalf of the 043 Study Group. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm. 2002; 109: 489-502.
6. Van Horn G, Hassenbusch SJ, Zouridakis G, Mullani NA, Wilde MC, Papanicolaou AC. Pallidotomy: a comparison of responders and nonresponders. Neurosurgery. 2001; 48: 263-271.
7. Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Neurology. 1999; 53: 573-579.
8. Ziegler M, Castro-Caldas A, Del Signore S, Rascol O. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study. Mov Disord. 2003; 18: 418-425.
9. Stern MB, Marek KL, Friedman J, et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord. 2004; 19: 916-923.
10. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study. JAMA. 1997; 278: 125-130.
11. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the Unified Parkinson's Disease Rating Scale. Mov Disord 2006; 21: 1200-1207.
12. Rascol O. Defining a minimal clinically relevant difference for the Unified Parkinson's Rating Scale: an important but still unmet need. Mov Disord. 2006; 21: 1059-1061.
13. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the Unified Parkinson's Disease Rating Scale. Arch Neurol. 2010; 67: 64-70.
14. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005; 62: 241-248.
15. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003; 56: 395-407.